BioCentury
ARTICLE | Company News

Lundbeck neurology news

July 30, 2012 7:00 AM UTC

H. Lundbeck said it received from the European Commission a statement of objections regarding deals with four generic companies for Lundbeck's antidepressant Celexa citalopram. Lundbeck, which did not disclose the contents of the statement of objections, said it believes its business practices are consistent with all relevant national and EU competition legislation. The company said it does not believe its practice has violated European competition law. Lundbeck is cooperating with the EC's investigation and will submit a reply to the statement of objections to address the concerns raised. The company said it "vigorously" opposes the allegations, which should be rejected as "groundless." ...